Sonoma Pharmaceuticals (FRA:O8Z) Tariff Resilience Score: 5/10 (As of Jul. 29, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

FRA:O8Z Sonoma Pharmaceuticals Inc FRA:O8Z
34 GF Score
Price €2.72
GF Value €6.04
! 4 Warning Signs
View Full Analysis

What is Sonoma Pharmaceuticals Tariff Resilience Score?

Sonoma Pharmaceuticals FRA:O8Z 34 Tariff Resilience Score is 5 as of Jul. 29, 2026. GuruFocus rates FRA:O8Z with a GF Score™ of 34/100 and a GF Value™ of €6.04. The stock has 4 warning signs investors should review. Among 1,027 Drug Manufacturers companies, Sonoma Pharmaceuticals ranks better than 84.42% on this metric.

Sonoma Pharmaceuticals has the Tariff Resilience Score of 5, which implies that the company might have Average Resilient.

Sonoma Pharmaceuticals has Sonoma Pharmaceuticals Inc has a global supply chain with manufacturing in the US and sales internationally. It faces moderate tariff risks on imported raw materials and exported products. The company has limited pricing power but can explore alternative suppliers to mitigate impacts.

Tariff Resilience Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more.

The company's exposure to international trade tariffs based on these criteria:

1. Global supply chain dependencies
2. Manufacturing locations versus sales markets
3. Import/export balance and percentage of revenue
4. Historical impact from previous tariff changes
5. Available mitigation strategies (alternative suppliers, pricing power)
6. Industry-specific tariff exemptions or vulnerabilities

Based on the research, GuruFocus believes Sonoma Pharmaceuticals might have Average Resilient.

Sonoma Pharmaceuticals  (FRA:O8Z) Tariff Resilience Score Explanation

The Tariff Resilience Score ranges from 0 to 10, with 10 as the most resilient. GuruFocus divided Moat Score into following 3 categories:

Tariff Resilience Score Resilience Level
7 - 10Highly Resilient
4 - 6Average Resilient
0 - 3Highly Vulnerable

Sonoma Pharmaceuticals Tariff Resilience Score Related Terms

FRA:O8Z vs YCBD, CVSI, AKAN: Tariff Resilience Score Comparison

For the Drug Manufacturers - Specialty & Generic subindustry, Sonoma Pharmaceuticals's Tariff Resilience Score, along with its competitors' market caps and Tariff Resilience Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Sonoma Pharmaceuticals Tariff Resilience Score vs Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Sonoma Pharmaceuticals's Tariff Resilience Score distribution charts can be found below:

* The bar in red indicates where Sonoma Pharmaceuticals's Tariff Resilience Score falls into.


FRA:O8Z
34GF Score
Sonoma Pharmaceuticals Inc FRA:O8Z
Tariff Resilience Score is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Tariff Resilience Score of 5 mean?
Sonoma Pharmaceuticals (FRA:O8Z) has a Tariff Resilience Score of 5 as of Jul. 29, 2026. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. According to the industry distribution chart, Sonoma Pharmaceuticals ranks #160 out of 1027 companies in the Drug Manufacturers industry, placing it in the top 15.6%.
Is Sonoma Pharmaceuticals' Tariff Resilience Score too high?
Sonoma Pharmaceuticals' current Tariff Resilience Score is 5. Based on the distribution chart, Sonoma Pharmaceuticals ranks #160 out of 1027 companies in the Drug Manufacturers industry, which is in the top quartile — a strong position relative to peers. Overall, Sonoma Pharmaceuticals has a GF Score™ of 34/100, reflecting its overall financial health beyond just this single metric.
How does Sonoma Pharmaceuticals' Tariff Resilience Score compare to YCBD and CVSI?
According to the Drug Manufacturers industry distribution chart, Sonoma Pharmaceuticals ranks #160 out of 1027 companies for Tariff Resilience Score. This places Sonoma Pharmaceuticals in the top 16% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Tariff Resilience Score for a Drug Manufacturers company?
A good Tariff Resilience Score depends on the Drug Manufacturers industry context. However, Tariff Resilience Score should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Tariff Resilience Score mean?
A high Tariff Resilience Score can signal that a stock is expensive relative to its fundamentals. Tariff Score is a ranking system developed by GuruFocus to measure a company's exposure to international trade tariffs, rated on a scale from 0 to 10. It takes into account key factors such as global supply chain dependencies, manufacturing locations versus sales markets, import / export balance and percentage of revenue, and more. Sonoma Pharmaceuticals's current Tariff Resilience Score is 5. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sonoma Pharmaceuticals stock overvalued right now?
Sonoma Pharmaceuticals (FRA:O8Z) has a current Tariff Resilience Score of 5. The stock's GF Value™ is €6.04, compared to a current price of €2.72 — trading 55% below its estimated fair value. The current Tariff Resilience Score is 5. Sonoma Pharmaceuticals' overall GF Score™ is 34/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Tariff Resilience Score calculated?
Tariff Resilience Score is calculated from a company's financial statements. For Sonoma Pharmaceuticals (FRA:O8Z), the current Tariff Resilience Score is 5 as of Jul. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Sonoma Pharmaceuticals (FRA:O8Z) Overvalued in 2026?

Based on GuruFocus' analysis, Sonoma Pharmaceuticals stock appears to be undervalued. The current stock price of €2.72 is trading 55% below its estimated GF Value™ of €6.04.

Key valuation signals for FRA:O8Z:

  • Tariff Resilience Score: 5
  • GF Value™: €6.04 vs. price of €2.72 (55% below fair value)
  • GF Score™: 34/100 with 4 warning signs

No single metric tells the full story. See the FRA:O8Z stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Sonoma Pharmaceuticals Business Description

Other Exchanges SNOA:USA
Address 5445 Conestoga Court, Suite 150, Boulder, CO, USA, 80301
Sonoma Pharmaceuticals Inc is a specialty pharmaceutical company operating in the United States. It is engaged in identifying, developing, and commercializing differentiated therapies for patients living with chronic skin conditions. The company focuses on the development and commercialization of therapeutic solutions in medical dermatology to treat skin conditions, such as acne, atopic dermatitis, and scarring. The key products of the company are Celacyn, Ceramax Skin Barrier Cream, Mondoxyne, Alevicyn, SebuDerm, Microcyn, and Microcyn which are available for various skin treatments such as scars, itchy skin, minor skin irritations, rashes, and others. The company derives revenue from the sale of products in the United States, Latin America, Europe, Asia, and other countries.
34GF Score

Get the complete analysis for FRA:O8Z

Tariff Resilience Score is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€2.72
Price
€6.04
GF Value